THALES
18.9.2023 14:01:30 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced the launch of CipherTrust Cloud Key Management's Hold Your Own Key (HYOK) in Oracle Cloud Infrastructure (OCI) across all 45 Oracle Cloud Regions—including the recently launched Oracle EU Sovereign Cloud—and OCI’s other distributed cloud offerings. To help meet continued customer demand and the accelerated growth of the OCI platform, HYOK will help OCI customers achieve their data sovereignty and other compliance objectives more easily by encrypting data in OCI with keys that are controlled and managed outside of the cloud platform. The new HYOK capabilities expand on existing support for Bring Your Own Key (BYOK) in OCI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918263668/en/
©Thales
According to the 2023 Thales Cloud Security Study, while the world has become cloud-first, operational complexity in cloud environments remains a significant obstacle for organizations. Overall, cloud security awareness has improved, but concerns around securing data are also rising, with over half (55 percent) of security professionals indicating it’s more complex to manage data in the cloud than it is in on-premises environments. As a result, as cloud usage grows, organizations need a new way to effectively secure cloud environments.
The CipherTrust Cloud Key Management integration enables OCI customers to store and manage their encryption keys outside OCI in a virtual or physical appliance that is entirely under their control and outside of the cloud. Customers can also localize their encryption keys wherever they choose and maintain control of their encrypted data in cloud environments. This approach helps address some of the key privacy and data sovereignty requirements organizations face while making it easier to demonstrate compliance to regulators.
The availability of the Thales external key management solution can help accelerate the move of sensitive data into Oracle Cloud Regions by storing the key in a location that is different than the encrypted data. This enables customers to maintain the same process for managing and controlling encryption keys, whether those keys are used on-premises or in the cloud
Thales CipherTrust Cloud Key Management, the industry-leading multi-cloud encryption key lifecycle management solution, alleviates operational barriers across clouds and hybrid environments. The HYOK functionality gives OCI customers the external key management capabilities necessary to navigate today’s cloud-driven landscape and remain in charge of their data, not just in OCI, but across other cloud providers.
Todd Moore, Vice President of Data Security Products at Thales: “Businesses are increasingly shifting away from legacy on-premises deployments and need assistance in moving their data to the cloud while maintaining security and compliance. As the industry leader in external key management, we’re proud to be the first to support HYOK features in OCI, equipping OCI customers with the necessary solutions to be successful in this journey. To further this best-in-class experience for our combined customer base, Thales is also the first supporting vendor for Oracle EU Sovereign Cloud initiatives.”
Jeppe Larsen, Senior Vice President, OCI Security and Identity at Oracle: “We’re dedicated to making OCI the most trusted cloud for security-sensitive workloads, including those in highly regulated regions and industries. Oracle EU Sovereign Cloud helps customers operating in Europe to address their data sovereignty requirements, and the HYOK integration with Thales enhances that offering. In addition, this partnership and integration will benefit U.S. customers in regulated industries such as financial services by enabling them to take full advantage of OCI, with the privacy and security benefits of HYOK from Thales.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. |
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918263668/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom